The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs

Molecular Genetics and Metabolism

Volumn 112, Issue 1, 2014, Pages 44-48

  Higuchi, Takashi ^a   Kawagoe, Shiho ^a   Otsu, Makoto ^b   Shimada, Yohta ^a   Kobayashi, Hiroshi ^a   Hirayama, Reimi ^a,c   Eto, Koji ^d   Ida, Hiroyuki ^a   Ohashi, Toya ^a   Nakauchi, Hiromitsu ^b   Eto, Yoshikatsu ^a,c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Institute of Neurological Disorders   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Acid glucosidase; IPS cell; Pompe disease; Ultrastructure

Indexed keywords

ALKALINE PHOSPHATASE; KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RETROVIRUS VECTOR; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRANSCRIPTION FACTOR SOX2; ALPHA GLUCOSIDASE; GLYCOGEN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CYTOPLASM; DRUG EFFECT; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT DISEASE; ONCOGENE C MYC; PERIODIC ACID SCHIFF STAIN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; TRANSGENE; BIOLOGICAL MODEL; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; FIBROBLAST; GLYCOGEN STORAGE DISEASE TYPE II; METABOLISM; PATHOLOGY; SKIN;

ALPHA-GLUCOSIDASES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; SKIN;

EID: 84899642736     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.02.012     Document Type: Article

References (19)

1. Hers H.G. alpha-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease). Biochem. J. 1963, 86:11-16.
2. Koster J.F., Busch H.F., Slee R.G., Van Weerden T.W. Glycogenosis type II: the infantile- and late-onset acid maltase deficiency observed in one family. Clin. Chim. Acta 1978, 87(3):451-453.
3. Kishnani P.S., Corzo D., Leslie N.D., Gruskin D., Van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., Bauer M.S., Jokic M., Tsai C.E., Tsai B.W., Morgan C., O'Meara T., Richards S., Tsao E.C., Mandel H. Early treatment with alglucosidasealfa prolongs long-term survival of infants with Pompe disease. Pediatr. Res. 2009, 66(3):329-335.
4. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
5. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
6. Matsumoto Y., Hayashi Y., Schlieve C.R., Ikeya M., Kim H., Nguyen T.D., Sami S., Baba S., Barruet E., Nasu A., Asaka I., Otsuka T., Yamanaka S., Conklin B.R., Toguchida J., Hsiao E.C. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J. Rare Dis. 2013, 8(1):190. (Epub ahead of print).
7. Panicker L.M., Miller D., Park T.S., Patel B., Azevedo J.L., Awad O., Masood M.A., Veenstra T.D., Goldin E., Stubblefield B.K., Tayebi N., Polumuri S.K., Vogel S.N., Sidransky E., Zambidis E.Z., Feldman R.A. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(44):18054-18059.
8. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., Svendsen C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457(7227):277-278.
9. Higurashi N., Uchida T., Lossin C., Misumi Y., Okada Y., Akamatsu W., Imaizumi Y., Zhang B., Nabeshima K., Mori M.X., Katsurabayashi S., Shirasaka Y., Okano H., Hirose S. A human Dravet syndrome model from patient induced pluripotent stem cells. Mol. Brain 2013, 6(19). (Epub ahead of print).
10. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134(5):877-886.
11. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., Wichterle H., Henderson C.E., Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321(5893):1218-1221.
12. Mali P., Ye Z., Hommond H.H., Yu X., Lin J., Chen G., Zou J., Cheng L. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 2008, 26(8):1998-2005.
13. Huang H.P., Chen P.H., Hwu W.L., Chuang C.Y., Chien Y.H., Stone L., Chien C.L., Li L.T., Chiang S.C., Chen H.F., Ho H.N., Chen C.H., Kuo H.C. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum. Mol. Genet. 2011, 20(24):4851-4864.
14. Kawagoe S., Higuchi T., Meng X.L., Shimada Y., Shimizu H., Hirayama R., Fukuda T., Chang H., Nakahata T., Fukada S., Ida H., Kobayashi H., Ohashi T., Eto Y. Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells. Mol. Genet. Metab. 2011, 104(1-2):123-128.
15. Bajel A., Bazargan A., Doery J., Roy S. Lymphocyte vacuolation: clue to inherited metabolic disease. Pathology 2010, 42(7):699-700.
16. Prater S.N., Patel T.T., Buckley A.F., Mandel H., Vlodavski E., Banugaria S.G., Feeney E.J., Raben N., Kishnani P.S. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J. Rare Dis. 2013, 8(1):90. (Epub ahead of print).
17. Kawagoe S., Higuchi T., Otaka M., Shimada Y., Kobayashi H., Ida H., Ohashi T., Okano H.J., Nakanishi M., Eto Y. Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp). Mol. Genet. Metab. 2013, 109(4):386-389.
18. Shimada Y., Kobayashi H., Kawagoe S., Aoki K., Kaneshiro E., Shimizu H., Eto Y., Ida H., Ohashi T. Endoplasmic reticulum stress induces autophagy through activation of p38 MAPK in fibroblasts from Pompe disease patients carrying c.546G>T mutation. Mol. Genet. Metab. 2011, 104(4):566-573.
19. Tolar J., Park I.H., Xia L., Lees C.J., Peacock B., Webber B., McElmurry R.T., Eide C.R., Orchard P.J., Kyba M., Osborn M.J., Lund T.C., Wagner J.E., Daley G.Q., Blazar B.R. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood 2011, 117(3):839-847.